Articles tagged with Tumor Cells
A research team has assembled a detailed atlas of bone marrow cells from AML patients, revealing six stages of white blood cell development and a role for differentiated tumor cells in suppressing immune responses. The study may lead to personalized therapies targeting specific AML cell types.
Researchers develop a new assay to measure the eco-evolutionary interactions between sensitive and resistant tumor cells in non-small cell lung cancer. The study finds that by applying drug or eliminating fibroblasts, it is possible to 'treat the game', allowing for coopting of evolution to help patients
Researchers at the University of California San Diego discovered that breast tissue stiffening triggers multiple pathways to promote cancer cell formation. The study, published in PNAS, found that a subpopulation of mammary cells do not respond to stiffening, potentially leading to fewer or smaller primary tumors.
A new study has identified a pair of genes that can mimic the effects of BRCA proteins, potentially making tumor cells susceptible to PARP inhibitors. The researchers found that targeting these genes could improve treatment options for people with breast or ovarian cancer caused by BRCA defects.
Researchers discovered that STAT5B facilitates leukemogenesis in B-cell acute lymphocytic leukemia. They found that the absence of STAT5B increases interferon response and suppresses transformation. This understanding may enable precision medicine strategies to treat disease.
CKAP4, a plasma membrane protein, is released from pancreatic cancer cells in exosomes, allowing for its detection in serum. Researchers developed anti-CKAP4 monoclonal antibodies that block tumor signaling and inhibit growth, providing a potential therapeutic intervention.
The foundation awarded grants to nine early-career scientists working on novel approaches to fighting cancer. The recipients will receive up to four years of funding to explore their projects, which include gene editing technology CRISPR and single cell sequencing techniques.
Researchers have engineered immune cells to target different types of pediatric solid tumors, including brain tumors, with promising results. The treatment uses a surface marker called B7-H3, which is expressed on most pediatric cancer cells, and has been shown to eradicate tumors in mice.
Researchers at the University of Basel have developed a novel differentiation therapy that converts breast cancer cells into fat cells, impeding the formation of metastases in mice. The therapy combines two active substances, Rosiglitazone and Trametinib, to suppress tumor growth and spread.
Researchers propose a new perspective on cancer origins, highlighting the importance of mutation sequence and cell type in tumor growth and response to therapy. This approach may lead to new avenues for cancer prevention and treatment.
Researchers have identified a unique actin filament nanoscaffold triggered by molecular signals, which expands our understanding of cell movement. The discovery could yield insights into cancer metastasis, wound healing, and other cell-motility-related conditions.
Researchers at Far Eastern Federal University propose using stem cell activation to target glioma tumors. The approach aims to bring cancerous stem cells into an active state, making them vulnerable to chemotherapy. This method has been approved for publishing and is considered promising despite its risks.
Researchers examined cancer metabolism using flux-balance analysis and found that the Warburg effect provides a growth advantage for tumors, while glutamine addiction does not. The study also sheds light on the relationship between healthy cells and tumor cells under the reverse Warburg effect.
Researchers investigated nanomaterials' potential to activate the body's antitumor immune response. The study found that biomaterials can induce immunogenic cell death, leading to a decrease in metastases and an increase in long-term survival rates.
Researchers have identified a molecular mechanism that allows tumor cells to eliminate their neighbors through mechanical competition. The study found that compressed cells are killed by modulated EGFR/ERK signal, which is decreased and then leads to cell death. This discovery suggests a potential therapeutic strategy to halt tumor growth
Researchers at CCNY and Yale developed a new efficient computational model to simulate the behavior of soft, shape-changing cells. The model provides accurate capture of particle deformation and allows easy adjustment of cell-cell interactions, enabling studies on tumor growth and embryonic development.
Researchers at Osaka University have developed an AI-based system that can automatically differentiate between various types of cancer cells using microscopic images. The system achieved higher accuracy than human judgment, making it a potential game-changer in cancer diagnosis and treatment.
A new combined action drug was developed by Russian scientists using ionizing radiation and bacterial toxin, showing a 2,200 times stronger effect than separate use. The drug selectively targets tumor cells and facilitates visualization of tumors, making it a diagnostic tool for cancer treatment.
Researchers at Lund University identified three types of connective tissue cells that affect breast cancer development and metastasis. Patients with vascular fibroblasts or matrix fibroblasts in their tumours have a worse prognosis.
Researchers identified genetic changes that enable tumor cells to evade immune detection after stem cell transplant. Telomere length is linked to risk of death from high-dose chemotherapy in MDS patients.
Researchers used single-cell RNA sequencing to study gene expression in individual cells and identify unique therapeutic targets for cancers that form in specific cell types. The study found that mutations in certain genes can make cells vulnerable to apoptosis, providing a potential way to prevent or treat cancer.
Researchers at Max Delbrück Center develop strategy to selectively make cancer cells aggressive, making them vulnerable to anti-inflammatory substance. This approach aims to overcome chemotherapy resistance in certain types of cancer, such as non-small cell lung cancer.
Scientists visualize immune system's action on tumor development, revealing its impact on cancer cell heterogeneity. The study highlights the potential for optimizing therapeutic combinations and sequences to improve immunotherapy outcomes.
A study published in Cell Reports identified an enzyme on the surface of some lung cancer cells that helps feed the cancer, making it a promising treatment target. The enzyme, TMPRSS11B, promotes tumor growth by encouraging lactate export and may be susceptible to antibody or small molecule therapy.
Researchers have developed a new method to identify differences between single cells using single nucleotide variants, which can eliminate biases in traditional sequencing methods. This technique uses variant information to retrieve gene expression data, enabling better identification of tumor subpopulations.
Researchers identified TP63 as the culprit behind aggressive pancreatic cancer's addictive behavior. Suppressing its activity could lead to a tumor's demise. The study aims to understand why TP63 gets active in some patients' pancreas, with the goal of developing a treatment to improve their survival.
Researchers at Johns Hopkins Medicine have found a link between low levels of specific microRNA molecules and the development of pediatric brain tumors. Increasing these molecules may potentially treat low-grade gliomas, which affect mostly school-age children and young adults.
Researchers developed a gene analysis approach to spot immune cells in tumors, which could help doctors choose best treatments and predict therapy responses. This new method, called ImSig, provides a detailed picture of tumors and will aid scientists in studying the impact of immune cell types on cancer growth.
Scientists have developed novel conjugates made from antibodies and a kinesin spindle protein inhibitor, showing high effectiveness in vitro and tumor models. The linker between components allows for tuning the activity of the cytostatic drug, reducing side effects in cancer treatment.
Biologists at UC San Diego have discovered a human gene that inhibits HIV and makes tumor cells sensitive to DNA-damaging agents. The researchers found that the Schlafen 11 protein blocks the synthesis of viral proteins, allowing tumor cells to survive.
Researchers have used high-resolution electron microscopy to reveal how an anti-cancer virus interacts with tumor cells, increasing its potential. The Seneca Valley Virus selectively targets a receptor found in over 60% of human cancers, offering a promising approach for cancer treatment.
Researchers at Cold Spring Harbor Laboratory have identified molecular signals that can convert tumor-promoting fibroblasts into beneficial ones in pancreatic tumors. By manipulating these signals, they aim to recruit tumor-restricting cells into the anticancer fight and develop a combination therapy approach.
Researchers at VIB and Ghent University have discovered a novel method to block immunosuppression in cancer by targeting the protein assembly that dampens immune responses. This breakthrough could lead to the development of new therapies to stimulate immunity against tumor cells.
A study found that cancer stem cells with MHC Class I molecules upregulate and retain CDK1 protein, allowing them to initiate tumor growth. Sox2 transcription factor plays a key role in maintaining their stemness.
Researchers are using pulsed electric fields to treat tumors, inducing cell death and stimulating the immune system. The technology delivers genes encoding cancer-fighting proteins into tumor cells, increases drug efficiency, and affects cell signaling.
A study published in Nature identified a tumor cell population responsible for resistance to therapy and tumor relapse in basal cell carcinoma. The researchers found that vismodegib promotes the differentiation of tumor cells, leading to their elimination, but also reveals a dormant population of tumor cells with active Wnt signaling.
Researchers have developed a novel T cell bispecific antibody that guides immune cells to HER2-positive breast cancer cells, offering a targeted and safe approach. The therapy has shown promise in tackling certain breast cancers by exclusively targeting cancerous cells.
A specific protein called TEAD1 has been identified as a key regulator of tumor migration in glioblastoma, a devastating form of brain cancer. By deactivating this protein, researchers may be able to stop tumor cells from migrating away from the main tumor mass, increasing the success rate and overall survival time for patients.
Researchers developed switchable fluorescent proteins that can be controlled by green and orange light, enabling the study of dynamic processes in living cells without harming them. The proteins' efficient photoswitching allows for super-resolution fluorescence microscopy, a method previously hampered by toxic irradiation.
Researchers genetically engineered olfactory ensheathing cells to carry an anticancer drug, reducing tumor growth and improving survival in a mouse model. The treatment delivered the medication directly to glioblastoma cells while sparing healthy tissue, leading to a significant reduction in tumor size and prolonged survival.
Researchers develop new theory to explain how tumors spread, revealing competition between forces that shape their growth. The 'active wetting' model suggests tumors behave like active drops, with cells creating forces and moving on their own.
Researchers at CWRU School of Medicine are exploring the role of long noncoding RNAs in colon cancer. They have identified potential targets for treatment, including lincDUSP, and found that depleting its levels can slow tumor growth.
A study found that bacteria in the intestines fuel tumor growth in the colon, with chronic inflammation having no effect on cancer development. Microbial therapy is considered a promising approach when more about bacterial flora composition is known.
Researchers developed an mRNA-based nanotherapeutic to reintroduce functional copies of PTEN into cancer cells, restoring tumor suppressor function and killing cancer cells. The therapy showed significant suppression of tumor growth and progression in mouse models of prostate cancer.
Researchers at Massachusetts General Hospital discovered how NF-2 gene mutations lead to hyper-responsiveness to growth factor signaling, driving out-of-control cellular proliferation. This phenomenon is mediated by macropinocytosis, a process that enables cells to engulf fluids and nutrients from their environment.
Researchers have developed a new method using TOF-SIMS to map the flow of biomolecules in and around solid tumors. This technique reveals how tumors signal to their microenvironment and sap local tissue resources.
Researchers found a synthetic chemical, KHS101, which disrupts the mitochondria and metabolism of glioblastoma cells, leading to their self-destruction. The study showed promising results in mice, with a 50% decrease in tumour growth and an increase in survival.
Researchers discovered elephants' ability to resist cancer stems from the 'zombie LIF6' gene, which kills cells poised to become cancerous. This strategy may inspire new treatments for humans by mimicking the gene's behavior or activating its existing copies.
A team of researchers has confirmed that healthy tumor hybrid cells contribute to metastasis by forming spontaneously in live animals. Gene expression profiles show a mix of genes from both cell types, aiding metastatic cells in survival and potential groundwork for other tumor cells.
Medical researchers from MSU propose a new targeted cancer therapy by increasing the activity of wild-type p53, which supports genetic stability and prevents malignant tumor formation. The study reveals that p53 also regulates metastasis formation through various programmed cell death pathways.
Researchers have found that the cell layer surrounding breast milk ducts acts as an active defense mechanism to prevent cancer cells from spreading, grabbing stray cells and pulling them back in up to 92% of the time. This discovery challenges previous assumptions about the myoepithelial layer's role in cancer invasion.
A study by Weizmann Institute researchers found that a gene normally protecting against cancer, p53, can switch allegiance in the tumor microenvironment, supporting cancer growth. Eliminating this protein from cancer-associated fibroblasts reduced their ability to promote tumor growth and metastasis.
AEP enhances checkpoint inhibitor drug effects on cancer cells and autoimmune diseases; measuring AEP levels may help identify patients responding to treatment with PD-1 inhibitors.
A magnetic wire used to snag scarce tumor cells could prove swift and effective for early cancer detection. The technique attracts up to 80 times more tumor cells than current methods, making it a potent tool to catch the disease earlier.
Researchers at Brigham and Women's Hospital have developed engineered cancer cells that can home in on and destroy tumors using CRISPR technology. The treatment shows promise in preclinical models across multiple types of cancer, establishing a potential roadmap for clinical translation.
Researchers at Georgia State University and Vanderbilt University Medical Center have identified xCT, an amino acid transporter, as a potential therapeutic target for non-small cell lung cancer. The study found that inhibiting xCT using sulfasalazine reduced tumor formation in laboratory tests and improved survival rates in mice.
Researchers identified a mechanism where tumor cells display both PD-L1 and PD-1 proteins, neutralizing the PD-L1 'brake' on T cells. This could explain why some patients don't respond to immunotherapy, suggesting alternative mechanisms may be employed by tumors.
Researchers have identified 52 distinct cell types in lung tumors, far more than previously thought, offering new avenues for treatment and research. The study's findings will help develop strategies to fight tumor growth and test new immunotherapy targets.
Researchers discovered that cancerous cells in an aggressive type of childhood brain tumour work together to infiltrate the brain. The study found that DIPG cells can exert a profound influence on each other, leading to tumour growth and spread.
Researchers identify epigenetic enzyme TET2 as a key player in controlling dormant tumor cells that can lead to cancer recurrence. A novel biomarker, 5-Hydroxymethylcytosine (5hmC), is also discovered to detect these treatment-resistant cells and predict patient outcomes.